New chemo strategy aims to shrink rare sinus tumors and avoid major surgery
NCT ID NCT07320508
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 20 times
Summary
This study is for people with a rare and hard-to-treat sinus cancer called sinonasal adenoid cystic carcinoma. Researchers are testing a method where a high dose of the chemotherapy drug epirubicin is delivered directly to the tumor through a small tube in an artery. After three treatments, doctors will check if the tumor is gone; if so, patients may avoid surgery and just get radiation. The goal is to see if this personalized approach is safe and effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eye and ENT Hospital, Fudan University
RECRUITINGShanghai, Xuhui Strict, 200031, China
Conditions
Explore the condition pages connected to this study.